Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

University of Alberta

$17,500.00

Neoantigens in cutaneous T-cell lymphoma

FY 2018-19

Summary
Mycosis fungoides (MF) is a type of skin cancer that presents with red patches on the skin. These patches can develop into tumours, marking advanced disease. The disease can then spread to other organs. MF is considered incurable and once patients develop tumours, they have only a 56% chance of surviving 5 years. There is an urgent need for advances in therapies. Immunotherapies work by using the patient’s immune system to fight tumour cells. These therapies can be non-specific, such as exposure to ultraviolet light in photopheresis, however MF tumours show no response to this. Immunotherapies can also be designed specifically to recognize tumour cells. Neoantigens are new, unique proteins produced only due to mutations in tumors and not by healthy cells. Hence targeting neoantigens with immunotherapy, whether specific or non-specific, has been highly effective in other cancers. Neoantigens have never been investigated in mycosis fungoides, and my project will aim to do this for the first time. My hypothesis is that MF has only a small number of neoantigens that stimulate the immune system, explaining its poor response to non-specific immunotherapies. To characterize neoantigens, I will use DNA sequences of MF samples compiled by our lab. I will then apply computer algorithms to detect mutations and predict what neoantigens will result and cause an immune response. Such a discovery could provide the foundation for new immunotherapies to be designed specifically to target neoantigens. I will also compare the MF neoantigen profile to another skin cancer in the same family, Sézary Syndrome. This will provide insight into whether a higher number of neoantigens are responsible for Sézary Syndrome’s superior response to non-specific immunotherapies such as photopheresis.
Program
Master's Award: Canada Graduate Scholarships
Location
Alberta, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
406301
Name
Sivanand Arunima
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Neoantigens in cutaneous T-cell lymphoma
Programtype2
Studentship Programs
Orgnameinp2
University of Alberta
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Cancer; Cutaneous T Cell Lymphoma; Dermatology; Genomics; Health; Immunotherapy; Mycosis Fungoides; Neoantigen; Skin; Tumor
Abstract
Mycosis fungoides (MF) is a type of skin cancer that presents with red patches on the skin. These patches can develop into tumours, marking advanced disease. The disease can then spread to other organs. MF is considered incurable and once patients develop tumours, they have only a 56% chance of surviving 5 years. There is an urgent need for advances in therapies. Immunotherapies work by using the patient’s immune system to fight tumour cells. These therapies can be non-specific, such as exposure to ultraviolet light in photopheresis, however MF tumours show no response to this. Immunotherapies can also be designed specifically to recognize tumour cells. Neoantigens are new, unique proteins produced only due to mutations in tumors and not by healthy cells. Hence targeting neoantigens with immunotherapy, whether specific or non-specific, has been highly effective in other cancers. Neoantigens have never been investigated in mycosis fungoides, and my project will aim to do this for the first time. My hypothesis is that MF has only a small number of neoantigens that stimulate the immune system, explaining its poor response to non-specific immunotherapies. To characterize neoantigens, I will use DNA sequences of MF samples compiled by our lab. I will then apply computer algorithms to detect mutations and predict what neoantigens will result and cause an immune response. Such a discovery could provide the foundation for new immunotherapies to be designed specifically to target neoantigens. I will also compare the MF neoantigen profile to another skin cancer in the same family, Sézary Syndrome. This will provide insight into whether a higher number of neoantigens are responsible for Sézary Syndrome’s superior response to non-specific immunotherapies such as photopheresis.
Competitiondate
201812
Approvedterm2
1 yr 0 mth
Pinamesdelim
Sivanand, Arunima
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~